Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 226 participants.

Also called NCT01743001

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 226 participants (enrolled count) (from the registry)
Sponsor
  • Actelion Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01743001
Other papers using this trial's data
  • Evaluation of Macitentan in Patients With Eisenmenger Syndrome Circulation, 2019-01-02 DOI, PubMed 30586694, PMC6314514 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Austria, Bulgaria, Chile, China, France, Germany, Greece, Israel, Malaysia, Mexico, Philippines, Poland, Portugal, Romania, Russia, Serbia, Spain, Türkiye, United Kingdom, Vietnam (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01743001. Randomized; quadruple masking; primary purpose treatment. Start 2013-05-21 (actual); primary completion 2016-12-01 (actual). Results posted on 2018-01-30.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome
Acronym
MAESTRO
Condition
Pulmonary Arterial Hypertension
Intervention (Drug)
Macitentan 10 mg
Intervention (Drug)
Placebo
Lead sponsor
Actelion (class: industry)

Record details

Record id
cardio:ct-nct01743001
Content hash
99ba44afa3e59b426c4c166fee04b8d04f8ff3b0e45c01efd72e7ac6c0832524